Aclaris Therapeutics, Inc. (NASDAQ:ACRS)‘s stock had its “outperform” rating reiterated by research analysts at JMP Securities in a report released on Friday. They presently have a $39.00 target price on the biotechnology company’s stock. JMP Securities’ target price would indicate a potential upside of 42.08% from the company’s current price.

Other research analysts have also issued research reports about the stock. BidaskClub upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 16th. ValuEngine upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. Guggenheim restated a “buy” rating and issued a $40.00 price target on shares of Aclaris Therapeutics in a research report on Tuesday, July 4th. Jefferies Group LLC reiterated a “buy” rating and set a $36.00 price objective on shares of Aclaris Therapeutics in a research report on Wednesday, June 28th. Finally, Cantor Fitzgerald set a $50.00 price objective on shares of Aclaris Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $40.00.

Shares of Aclaris Therapeutics (NASDAQ:ACRS) traded up 0.26% on Friday, hitting $27.45. The stock had a trading volume of 329,358 shares. Aclaris Therapeutics has a 12-month low of $20.15 and a 12-month high of $33.25. The company’s market cap is $733.90 million. The stock has a 50 day moving average price of $26.61 and a 200-day moving average price of $27.82.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.68) by $0.12. On average, equities analysts expect that Aclaris Therapeutics will post ($3.10) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “JMP Securities Reiterates “Outperform” Rating for Aclaris Therapeutics, Inc. (ACRS)” was posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/09/09/jmp-securities-reiterates-outperform-rating-for-aclaris-therapeutics-inc-acrs.html.

In other news, Director Andrew N. Schiff acquired 108,601 shares of the stock in a transaction on Wednesday, August 16th. The shares were purchased at an average cost of $23.02 per share, for a total transaction of $2,499,995.02. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 16.30% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of ACRS. Teachers Advisors LLC grew its position in Aclaris Therapeutics by 24.9% during the 4th quarter. Teachers Advisors LLC now owns 17,249 shares of the biotechnology company’s stock worth $468,000 after purchasing an additional 3,435 shares in the last quarter. Nationwide Fund Advisors grew its position in Aclaris Therapeutics by 8.3% during the 1st quarter. Nationwide Fund Advisors now owns 6,627 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 510 shares in the last quarter. Strs Ohio purchased a new position in Aclaris Therapeutics during the 1st quarter worth approximately $629,000. Wells Fargo & Company MN grew its position in Aclaris Therapeutics by 91.3% during the 1st quarter. Wells Fargo & Company MN now owns 12,359 shares of the biotechnology company’s stock worth $369,000 after purchasing an additional 5,900 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in Aclaris Therapeutics by 269.0% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,801 shares of the biotechnology company’s stock worth $143,000 after purchasing an additional 3,500 shares in the last quarter. Hedge funds and other institutional investors own 95.79% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Analyst Recommendations for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.